DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
Relentlessly innovative, NuVasive develops and markets minimally disruptive surgical products and procedures for the spine. From its inception, it has focused on creating products, such as its nerve avoidance monitoring system, that contribute to faster, less invasive surgical procedures, speedier recovery times for patients, and shorter hospital stays.
NuVasive went public in 2004.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.